How big is Assertio Holdings, Inc.?

As of Jun 18, Assertio Holdings, Inc. has a market capitalization of 63.40 million, with net sales of 119.00 million and a net profit of -30.61 million over the latest four quarters. The balance sheet shows shareholder's funds of 121.08 million and total assets of 284.73 million.

As of Jun 18, Assertio Holdings, Inc. has a market capitalization of 63.40 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 119.00 million for the latest four quarters, while the net profit for the same period was -30.61 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 121.08 million and total assets of 284.73 million.

What does Assertio Holdings, Inc. do?

Assertio Holdings, Inc. is a micro-cap specialty pharmaceutical company with recent net sales of $26 million and a net loss of $14 million. It operates in the Pharmaceuticals & Biotechnology industry and has a market cap of $63.40 million.

Overview: <BR>Assertio Holdings, Inc. is a specialty pharmaceutical company that operates in the Pharmaceuticals & Biotechnology industry and falls within the micro-cap market segment.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 26 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 63.40 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.39 <BR>Return on Equity: -21.61% <BR>Price to Book: 0.58<BR><BR>Contact Details: <BR>Address: 100 S. Saunders Road, Suite 300, LAKE FOREST IL: 60045 <BR>Tel: ['1 224 4197106', '1 510 7448000'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.assertiotx.com/

Should I buy, sell or hold Assertio Holdings, Inc.?

Is Assertio Holdings, Inc. overvalued or undervalued?

As of November 8, 2023, Assertio Holdings, Inc. is considered a risky investment due to its overvaluation, poor financial metrics, and significant underperformance compared to peers and the S&P 500.

As of 8 November 2023, the valuation grade for Assertio Holdings, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.58, an EV to EBITDA of 6.51, and a negative ROCE of -39.77%. <BR><BR>When compared to peers, Assertio's valuation appears unfavorable; for instance, Ocular Therapeutix, Inc. has a more severe EV to EBITDA of -5.2132, while Vanda Pharmaceuticals, Inc. shows an EV to EBITDA of 1.1136. The company's recent stock performance has been notably poor, with a year-to-date return of -27.54%, significantly underperforming the S&P 500's 2.44% return in the same period. This combination of factors suggests that Assertio Holdings, Inc. is not a favorable investment at its current valuation.

Is Assertio Holdings, Inc. technically bullish or bearish?

As of September 10, 2025, Assertio Holdings, Inc. shows a neutral technical trend with mixed signals, having outperformed the S&P 500 in the short term but underperformed over the past year.

As of 10 September 2025, the technical trend for Assertio Holdings, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is bullish, while the RSI is bearish, indicating some conflicting momentum. Moving averages on the daily chart are bullish, supporting a potential upward movement. However, the overall trend remains sideways, suggesting a lack of clear direction.<BR><BR>In terms of performance, Assertio has outperformed the S&P 500 over the past week and month, with returns of 21.05% and 20.20% respectively, but has significantly underperformed over longer periods, including a -25.02% return over the past year compared to the S&P 500's 17.14%.